trending Market Intelligence /marketintelligence/en/news-insights/trending/a7YnGyukKMiqGescfpjFjQ2 content esgSubNav
In This List

Ligand agrees to reduced royalty rate on sales of medical device

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Ligand agrees to reduced royalty rate on sales of medical device

Ligand Pharmaceuticals agreed to a reduced royalty rate on the sales of CanGaroo in exchange for $10 million.

Aziyo Biologics will make the payment, following which Ligand will receive a 5% royalty on the sales of the medical device, which is intended to securely hold cardiovascular implantable electronic devices such as pacemakers and defibrillators.

Ligand had secured the rights to the device's royalty in May 2016 from CorMatrix Cardiovascular Inc. in exchange for a $17.5 million payment. The agreement provided for a 20% royalty on the sales of the device as well as others.

CorMatrix Cardiovascular has now transferred the commercial rights of CanGaroo to Aziyo Biologics.

Aziyo will pay Ligand up to $10 million in additional, sales-based milestones tied to the commercial success of the currently-marketed products and extend the term on these royalties by one year as part of the royalty rate reduction.